Bauer Amy M, Parker Melissa M, Schillinger Dean, Katon Wayne, Adler Nancy, Adams Alyce S, Moffet Howard H, Karter Andrew J
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356560, Seattle, WA, 98195-6560, USA,
J Gen Intern Med. 2014 Aug;29(8):1139-47. doi: 10.1007/s11606-014-2845-6.
Depression and adherence to antidepressant treatment are important clinical concerns in diabetes care. While patient-provider communication patterns have been associated with adherence for cardiometabolic medications, it is unknown whether interpersonal aspects of care impact antidepressant medication adherence.
To determine whether shared decision-making, patient-provider trust, or communication are associated with early stage and ongoing antidepressant adherence.
Observational new prescription cohort study.
Kaiser Permanente Northern California.
One thousand five hundred twenty-three adults with type 2 diabetes who completed a survey in 2006 and received a new antidepressant prescription during 2006-2010.
Exposures included items based on the Trust in Physicians and Interpersonal Processes of Care instruments and the Consumer Assessment of Healthcare Providers and Systems (CAHPS) communication scale. Measures of adherence were estimated using validated methods with physician prescribing and pharmacy dispensing data: primary non-adherence (medication never dispensed), early non-persistence (dispensed once, never refilled), and new prescription medication gap (NPMG; proportion of time without medication during 12 months after initial prescription).
After adjusting for potential confounders, patients' perceived lack of shared decision-making was significantly associated with primary non-adherence (RR = 2.42, p < 0.05), early non-persistence (RR = 1.34, p < 0.01) and NPMG (estimated 5% greater gap in medication supply, p < 0.01). Less trust in provider was significantly associated with early non-persistence (RRs 1.22-1.25, ps < 0.05) and NPMG (estimated NPMG differences 5-8%, ps < 0.01).
All patients were insured and had consistent access to and quality of care.
Patients' perceptions of their relationships with providers, including lack of shared decision-making or trust, demonstrated strong associations with antidepressant non-adherence. Further research should explore whether interventions for healthcare providers and systems that foster shared decision-making and trust might also improve medication adherence.
抑郁症及对抗抑郁药物治疗的依从性是糖尿病护理中的重要临床问题。虽然患者与医护人员的沟通模式与心血管代谢药物的依从性有关,但护理中的人际因素是否会影响抗抑郁药物的依从性尚不清楚。
确定共同决策、患者与医护人员之间的信任或沟通是否与早期及持续的抗抑郁药物依从性有关。
观察性新处方队列研究。
北加利福尼亚州凯撒医疗集团。
1523名2型糖尿病成年患者,他们于2006年完成了一项调查,并在2006年至2010年期间接受了新的抗抑郁药物处方。
暴露因素包括基于医患信任和护理人际过程工具以及医疗服务提供者和系统消费者评估(CAHPS)沟通量表的项目。使用经过验证的方法,根据医生处方和药房配药数据估算依从性指标:初次不依从(从未配药)、早期持续性差(配药一次,从未再取药)以及新处方药物间隔(NPMG;初始处方后12个月内无药时间的比例)。
在对潜在混杂因素进行调整后,患者感知到的共同决策缺乏与初次不依从(风险比[RR]=2.42,p<0.05)、早期持续性差(RR=1.34,p<0.01)和NPMG(估计药物供应差距大5%,p<0.01)显著相关。对医护人员的信任度较低与早期持续性差(RR为1.22 - 1.25,p<0.05)和NPMG(估计NPMG差异为5 - 8%,p<0.01)显著相关。
所有患者均有保险,且能持续获得医疗服务,医疗质量一致。
患者对其与医护人员关系的认知,包括共同决策的缺乏或信任的缺失,与抗抑郁药物不依从性密切相关。进一步的研究应探讨针对促进共同决策和信任的医疗服务提供者及系统的干预措施是否也能提高药物依从性。